Genetic mutation diminishes drug response in some cancer patients

Researchers at Mass General Brigham have discovered a key mutation that may be a driving factor in resistance to certain drugs used to treat cancer.

Related Keywords

Dejan Juric ,Therapies Investigational Cancer Therapeutics Program ,Termeer Center ,Cancer Center ,Boston Based Mass General Brigham ,Targeted Therapies ,Investigational Cancer Therapeutics Program ,Mass General Cancer ,Pi3k ,Breast Cancer ,Alpelisib ,Utation ,Resistance ,Ik3ca Gene ,Rug Binding ,Investigational Cancer Therapeutics ,